The transcriptional repressor REV-ERB as a novel target for disease
- 1 September 2020
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 30 (17) , 127395
Abstract
No abstract availableKeywords
Funding Information
- Cancer Research UK
- Engineering and Physical Sciences Research Council
This publication has 66 references indexed in Scilit:
- Synthesis and SAR of tetrahydroisoquinolines as Rev-erbα agonistsBioorganic & Medicinal Chemistry Letters, 2012
- Redox, haem and CO in enzymatic catalysis and regulationBiochemical Society Transactions, 2012
- Regulation of circadian behaviour and metabolism by REV-ERB-α and REV-ERB-βNature, 2012
- Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonistsNature, 2012
- Thiol-disulfide Redox Dependence of Heme Binding and Heme Ligand Switching in Nuclear Hormone Receptor Rev-erbβJournal of Biological Chemistry, 2011
- Identification of SR8278, a Synthetic Antagonist of the Nuclear Heme Receptor REV-ERBACS Chemical Biology, 2010
- Picosecond primary structural transition of the heme is retarded after nitric oxide binding to heme proteinsProceedings of the National Academy of Sciences, 2010
- Negative feedback maintenance of heme homeostasis by its receptor, Rev-erbαGenes & Development, 2009
- Regulation of Bile Acid Synthesis by the Nuclear Receptor Rev-erbαGastroenterology, 2008
- Bifunctional Role of Rev-erbα in Adipocyte DifferentiationMolecular and Cellular Biology, 2008